A detailed history of Algert Global LLC transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Algert Global LLC holds 39,292 shares of PCVX stock, worth $3.35 Million. This represents 0.12% of its overall portfolio holdings.

Number of Shares
39,292
Previous 34,752 13.06%
Holding current value
$3.35 Million
Previous $2.62 Million 71.11%
% of portfolio
0.12%
Previous 0.09%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$70.52 - $117.12 $320,160 - $531,724
4,540 Added 13.06%
39,292 $4.49 Million
Q2 2024

Aug 14, 2024

BUY
$60.06 - $78.77 $1.29 Million - $1.69 Million
21,442 Added 161.1%
34,752 $2.62 Million
Q1 2024

May 14, 2024

SELL
$59.79 - $81.05 $64,573 - $87,534
-1,080 Reduced 7.51%
13,310 $909,000
Q4 2023

Feb 14, 2024

SELL
$45.35 - $63.41 $471,640 - $659,464
-10,400 Reduced 41.95%
14,390 $904,000
Q3 2023

Nov 13, 2023

BUY
$46.0 - $53.1 $128,340 - $148,149
2,790 Added 12.68%
24,790 $1.26 Million
Q2 2023

Aug 14, 2023

BUY
$34.66 - $54.07 $5,649 - $8,813
163 Added 0.75%
22,000 $1.1 Million
Q1 2023

May 12, 2023

BUY
$36.27 - $47.2 $792,027 - $1.03 Million
21,837 New
21,837 $818,000
Q3 2022

Nov 15, 2022

BUY
$21.69 - $28.53 $350,965 - $461,643
16,181 Added 55.18%
45,505 $1.09 Million
Q2 2022

Aug 15, 2022

BUY
$17.68 - $26.58 $350,948 - $527,613
19,850 Added 209.52%
29,324 $638,000
Q1 2022

May 16, 2022

SELL
$17.46 - $26.36 $57,478 - $86,777
-3,292 Reduced 25.79%
9,474 $229,000
Q4 2021

Feb 14, 2022

BUY
$19.32 - $26.45 $28,593 - $39,146
1,480 Added 13.11%
12,766 $304,000
Q3 2021

Nov 15, 2021

BUY
$20.26 - $26.97 $228,654 - $304,383
11,286 New
11,286 $286,000

Others Institutions Holding PCVX

About Vaxcyte, Inc.


  • Ticker PCVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,315,100
  • Market Cap $5.06B
  • Description
  • Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...
More about PCVX
Track This Portfolio

Track Algert Global LLC Portfolio

Follow Algert Global LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Algert Global LLC, based on Form 13F filings with the SEC.

News

Stay updated on Algert Global LLC with notifications on news.